jueves, 17 de agosto de 2017

Vasopresina / Vasopressin

Agosto 15, 2017. No. 2781




Papel de la vasopresina en la práctica anestésica actual
Role of vasopressin in current anesthetic practice.
Korean J Anesthesiol. 2017 Jun;70(3):245-257. doi: 10.4097/kjae.2017.70.3.245. Epub 2017 May 26.
Abstract
Arginine vasopressin (AVP), also known as antidiuretic hormone, is a peptide endogenously secreted by the posterior pituitary in response to hyperosmolar plasma or systemic hypoperfusion states. When administered intravenously, it causes an intense peripheral vasoconstriction through stimulation of V1 receptors on the vascular smooth muscle. Patients in refractory shock associated with severe sepsis, cardiogenic or vasodilatory shock, or cardiopulmonary bypass have inappropriately low plasma levels of AVP ('relative vasopressin deficiency') and supersensitivity to exogenously-administered AVP. Low doses of AVP and its synthetic analog terlipressin can restore vasomotor tone in conditions that are resistant to catecholamines, with preservation of renal blood flow and urine output. They are also useful in the treatment of refractory arterial hypotension in patients chronically treated with renin-angiotensin system inhibitors, cardiac arrest, or bleeding esophageal varices. In the perioperative setting, they represent attractive adjunct vasopressors in advanced shock states that are unresponsive to conventional therapeutic strategies.
KEYWORDS: Arginine vasopressin; Hemorrhagic shock; Refractory hypotension; Septic shock; Terlipressin; Vasodilatory shock

XIV Congreso Virtual Mexicano de Anestesiología 2017
Octubre 1-Diciembre 31, 2017
Información / Information
California Society of Anesthesiologists
Reuniones / Events
Like us on Facebook   Follow us on Twitter   Find us on Google+   View our videos on YouTube 
Anestesiología y Medicina del Dolor

52 664 6848905

No hay comentarios: